Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (171-180 of 338) with videos related to

Pageof 34
Sort By:
Journal of Medical Internet Research|August 27, 2021
Feasibility of an Interactive Health Coaching Mobile App to Prevent Malnutrition and Muscle Loss in Esophageal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy: Prospective Pilot StudyKyungmi Yang, Dongryul Oh, Jae Myoung Noh, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2025
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancerJoo-Young Byun, Jinyong Kim, Sehhoon Park, et al.
Journal of Cancer Research and Clinical Oncology|June 17, 2010
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patientsJong-Mu Sun, Young-Woong Won, Seung Tae Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2022
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancerSehhoon Park, Jae Myoung Noh, Yoon-La Choi, et al.
Future Oncology (London, England)|May 2, 2024
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinomaJong-Mu Sun, Antoine Adenis, Peter C Enzinger, et al.
Practical Radiation Oncology|April 22, 2026
The implication of failure patterns after neoadjuvant chemoradiotherapy with small involved field in esophageal squamous cell carcinomaHyunju Shin, Dongryul Oh, Jae Myoung Noh, et al.
International Journal of Cancer|February 27, 2019
Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary diseaseSun Hye Shin, Hye Yun Park, Yunjoo Im, et al.
Cancer|November 2, 2004
A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinomaJong-Mu Sun, Wonshik Han, Seock-Ah Im, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 22, 2019
Diagnostic value of surveillance <sup>18</sup>F-fluorodeoxyglucose PET/CT for detecting recurrent esophageal carcinoma after curative treatmentSoo Jeong Kim, Seung Hyup Hyun, Seung Hwan Moon, et al.
Lung Cancer (Amsterdam, Netherlands)|October 30, 2012
Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancerHa Yeon Lee, Hee Kyung Ahn, Ji Yun Jeong, et al.
Pageof 34

Showing results (171-180 of 338) with videos related to

Sort By:
Pageof 34
Journal of Medical Internet Research|August 27, 2021
Feasibility of an Interactive Health Coaching Mobile App to Prevent Malnutrition and Muscle Loss in Esophageal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy: Prospective Pilot StudyKyungmi Yang, Dongryul Oh, Jae Myoung Noh, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2025
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancerJoo-Young Byun, Jinyong Kim, Sehhoon Park, et al.
Journal of Cancer Research and Clinical Oncology|June 17, 2010
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patientsJong-Mu Sun, Young-Woong Won, Seung Tae Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2022
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancerSehhoon Park, Jae Myoung Noh, Yoon-La Choi, et al.
Future Oncology (London, England)|May 2, 2024
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinomaJong-Mu Sun, Antoine Adenis, Peter C Enzinger, et al.
Practical Radiation Oncology|April 22, 2026
The implication of failure patterns after neoadjuvant chemoradiotherapy with small involved field in esophageal squamous cell carcinomaHyunju Shin, Dongryul Oh, Jae Myoung Noh, et al.
International Journal of Cancer|February 27, 2019
Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary diseaseSun Hye Shin, Hye Yun Park, Yunjoo Im, et al.
Cancer|November 2, 2004
A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinomaJong-Mu Sun, Wonshik Han, Seock-Ah Im, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 22, 2019
Diagnostic value of surveillance <sup>18</sup>F-fluorodeoxyglucose PET/CT for detecting recurrent esophageal carcinoma after curative treatmentSoo Jeong Kim, Seung Hyup Hyun, Seung Hwan Moon, et al.
Lung Cancer (Amsterdam, Netherlands)|October 30, 2012
Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancerHa Yeon Lee, Hee Kyung Ahn, Ji Yun Jeong, et al.
Pageof 34